Document is current

Article History

Received: 3 April 2025

Accepted: 9 August 2025

First Online: 26 August 2025

Declarations

:

: We obtained consent from all patients to conduct various clinical tests. This study was conducted in compliance with the Declaration of Helsinki. Informed consent was obtained from all patients while utilising anonymised data.

: Not applicable.

: S. Kubo has received speaking fees from Eli Lilly, GlaxoSmithKline, Bristol-Myers, Abbvie, Eisai, Pfizer, Astra-Zeneca and also research grants from Daiichi-Sankyo, Abbvie, Boehringer Ingelheim, and Astellas. S. Nakayamada has received consulting fees, speaking fees, lecture fees, and/or honoraria from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-Kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, Boehringer Ingelheim and Ayumi. Y. Miyazaki has received consulting fees, speaking fees, lecture fees, and/or honoraria from AstraZeneca, GlaxoSmithKline, Bristol-Myers, Astellas, Asahi-Kasei, AbbVie, Chugai, Sanofi, Eisai, Eli Lilly, and Boehringer Ingelheim. M. Ueno has received speaking fees from GlaxoSmithKline. Y. Tanaka has received speaking fees and/or honoraria from Gilead, Abbvie, Behringer-Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers, and Astra-Zeneca; received research grants from Asahi-Kasei, Abbvie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa, and Behringer-Ingelheim; and received consultant fees from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK, and Abbvie. The other authors have no conflicts of interest to declare.